论文部分内容阅读
目的探讨紫杉醇脂质体联合奈达铂治疗晚期食管癌的近期疗效和不良反应。方法紫杉醇脂质体联合奈达铂方案治疗23例晚期食管癌患者,紫杉醇脂质体135mg/m2,静脉滴注3h,d1;奈达铂70mg/m2,静脉滴注,d1,每21天为1个周期,2个周期化疗后进行疗效评价。结果 23例患者中,完全缓解(CR)1例,占4.3%;部分缓解(PR)8例,占34.8%;稳定(SD)10例,占43.5%;进展(PD)4例,占17.4%;总有效率(CR+PR)为39.1%。11例初治患者总有效率为54.5%(6/11),12例复治患者总有效率为25.0%(3/12)。化疗主要不良反应为骨髓移抑制。结论紫杉醇脂质体联合奈达铂治疗晚期食管癌疗效确切且安全性好。
Objective To investigate the short-term curative effect and side effects of paclitaxel liposome combined with nedaplatin in the treatment of advanced esophageal cancer. Methods paclitaxel liposome combined with nedaplatin regimen in 23 patients with advanced esophageal cancer, paclitaxel liposome 135mg / m2, intravenous infusion of 3h, d1; nedaplatin 70mg / m2, intravenous drip, d1 every 21 days 1 cycle, 2 cycles after chemotherapy efficacy evaluation. Results Among the 23 patients, complete remission (CR) occurred in 1 case (4.3%), partial remission (PR) in 8 cases (34.8%), stable (SD) in 10 cases, 43.5% and progression (PD) in 4 cases %; Total effective rate (CR + PR) was 39.1%. The total effective rate was 54.5% (6/11) in 11 newly diagnosed patients and 25.0% (3/12) in 12 retreatment patients. The main adverse reaction of chemotherapy is bone marrow metastasis inhibition. Conclusion paclitaxel liposomes combined with nedaplatin in the treatment of advanced esophageal cancer is effective and safe.